Figure 6.

Tumor control by Th/Tc17 CAR T cells is enhanced by human STING agonist 2,3-cGAMP. NT2 tumors were orthotopically injected into murine mammary pads. 21 d later, 25 µg of cGAMP was injected at a site distal to the tumor site, followed by injection of 3 × 10⁶ mock T cells, 7/15 CAR T cells, or Th/Tc17 CAR T cells (CD4⁺:CD8⁺ at ∼1:1 ratio). (A) Representative flow cytometry histograms of CAR T cells detection at in the TME (left) and summary of accumulation of CAR T cells (right). (B) Change in tumor area measured over 7 d after treatment. (C) Tumor area change 21 d after indicated therapy. (D) Kaplan–Meier survival curve for the treatment cohorts. Endpoint criteria for sacrifice was tumor area of ≥200 mm². Gating of flow cytometry data used fluorescence minus one controls for each individual experiment. Data are shown as mean ± SD; ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001; significance was determined by Student’s t test or log-rank Mantel–Cox test when comparing survival. n ≥ 5 mice per group with the data from at least two independent experiments, with the presented data pooled.